Compare iShares MSCI United Kingdom (FTSE) (EWU) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI United Kingdom (FTSE) vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? iShares MSCI United Kingdom (FTSE) trades at $46.91 (market cap $3.69B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: iShares MSCI United Kingdom (FTSE) is far larger — about 3.8× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and iShares MSCI United Kingdom (FTSE) is more actively traded (701,016 versus 4,325,710). Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI United Kingdom (FTSE) for 48 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| EWU | MRVI | |
|---|---|---|
Market Cap | $3.69B | $972.90M |
Volume | 701,016 | 4,325,710 |
Sector | Broad Market / Factor | Health |
52-Week High | $49.39 | $9.00 |
52-Week Low | $41.34 | $2.83 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | — | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWU trades at $46.82 with a modest 0.26% daily gain, though technical indicators signal a bearish trend with moving averages and overall momentum pointing downward. The stock faces headwinds from UK economic concerns including rising gilt yields and inflation pressures. Recent news highlights sector-specific volatility in UK banking and housing markets, creating a challenging environment for this UK-focused ETF.
The outlook remains cautious given macroeconomic pressures on UK assets. Investment opportunity exists for contrarian investors betting on UK recovery, but risks include persistent inflation, rising interest rates, and political uncertainty around upcoming budget decisions that could impact financial and housing sectors significantly.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI United Kingdom (FTSE)
EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.
Read more on EWU →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
